In a study, injecting an IL-1β antagonist to treat arthritis in rats and humans inhibited the IL-1Ra receptor, preventing the destruction of the extracellular matrix of chondrocytes.7 One study examined the effect of commercially available ACS on temporomandibular joint inflammatory disorders and reported promising results in treating TMJ arthritis using this product.8Another study reported that injecting commercially available ACS to treat arthritis decreased joint pain and improved joint function. The gene discussed is IL1B; the disease is arthritic joint disease.